Products
Ozuriftamab Biosimilar Monoclonal Antibody (ROR2) for Research
Cat No.: GMP-Bios-INN-1323
Anti-ROR2 therapeutic antibody (Pre-made Ozuriftamab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ozuriftamab (development code BA-3021) is a monoclonal antibody-drug conjugate targeting ROR2. It is developed by BioAtla for melanoma, non-small cell lung cancer, and ovarian cancer. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1323-1mg | 1mg | 3090 |
| GMP-Bios-INN-1323-10mg | 10mg | |
| GMP-Bios-INN-1323-100mg | 100mg | |
| GMP-Bios-INN-1323-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ozuriftamab biosimilar, Whole mAb, Anti-ROR2 Antibody: Anti-ROR2/Tyrosine-protein kinase transmembrane receptor ROR2/Neurotrophic tyrosine kinase/receptor-related 2 therapeutic antibody |
| INN Name | Ozuriftamab |
| Target | ROR2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | BioAtla |
| Conditions Approved | na |
| Conditions Active | Malignant Melanoma;Non-small cell lung cancer;Ovarian cancer;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
